WEX Pharmaceuticals Inc. is a biopharmaceutical company based in Vancouver, Canada and is developing a late-stage non-opioid analgesic, Halneuron®.
Halneuron is a highly selective sodium channel blocker and represents a breakthrough in painkiller technology:
Halneuron is entering into Phase III clinical trials for chemotherapy-induced neuropathic pain and concurrently being tested in other pain indications.
Halneuron® is a highly selective sodium channel blocker with the active ingredient Tetrodotoxin (TTX), which blocks pain signals from reaching the brain to relieve pain. Unlike opioids, Halneuron has no evidence of addictions to the user and does not have the same side effects as opioids.
WEX has conducted over 15 clinical trials with more than 500 patients treated to date with Halneuron®.
Halneuron has completed Phase I to Phase III clinical trials and is in the process of preparing for further pivotal, double-blinded, placebo-controlled trials.
Halneuron® is a selective sodium blocker based on Tetrodotoxin (TTX) that is known to block pain signals to relieve pain. Unlike opioids, Halneuron and TTX is not addictive to the user.
WEX has successfully conducted 15 clinical trials with TTX, with more than 700 people treated to date. Halneuron™ has successfully undergone Phase I to III trials and is in the process of preparing for a double-blinded, placebo-controlled Phase III trial.
